In line with these studies, it was demonstrated that antileukemic activity of the PKCβ inhibitor sotrastaurin (AEB071) in CLL, relies, besides PKCβ inhibition, on GSK3β activation associated with reduced expression of β-catenin and its targets c-myc, cyclin and CD44 [60]. Here, GSK3B is linked to B-cell chronic lymphocytic leukemia.